Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

SuperGreenToday Apr. 2 at 1:25 AM

$ACET Share Price: $6.90 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.14 – $0.17 Potential Upside: 52% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TheTurdFlusher Apr. 1 at 4:28 PM

$ACET man crazy this thing is still listed, the grift continues lol

0 · Reply

keepbuying Mar. 31 at 7:19 PM

$ACET would not be surprised to see an activist come at them given how below cash this is trading

0 · Reply

Nanu108 Mar. 31 at 3:11 AM

$ACET hot ACET today 10000 shares 52 low

0 · Reply

keepbuying Mar. 30 at 7:43 PM

$ACET catalysts coming soon-I’m continuing to buy low every day to keep my avg as low as possible..Orbimed and others paid 16/sh just this past Oct and there has been no negative news and they are now even closer to the data flips!

2 · Reply

Ugbjjvgg Mar. 30 at 11:17 AM

$ACET I got into this stock by following the huge purchase by Orbimed, looking at their previous picks they have done seriously well. It's only matter of time this thing rockets.

0 · Reply

DCZ Mar. 27 at 4:56 PM

$ACET bought more this morning

1 · Reply

keepbuying Mar. 25 at 2:12 PM

$ACET lots of data coming between now and June 30…. #biorunup Adicet closed the year with solid momentum, driven by strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the fourth quarter. Enrollment in our Phase 1 prula‑cel autoimmune study continues advancing ahead of expectations, supported by significant physician and patient interest in the study and FDA alignment that enables outpatient dosing for LN and SLE patients. We look forward to providing a clinical update in LN, SLE and SSc in the first half of this year," said Chen Schor, President and Chief Executive Officer of Adicet Bio.

0 · Reply

ChadWright85 Mar. 18 at 6:34 PM

$ACET Hard to see this turning around without a real catalyst.

1 · Reply

erevnon Mar. 13 at 2:56 PM

Guggenheim maintains Adicet Bio $ACET at Buy and lowers the price target from $128 to https://marketsblock.com/stock-upgrades-and-downgrades/

1 · Reply

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Jan 30, 2026, 7:00 AM EST - 2 months ago

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 7, 2026, 7:00 AM EST - 3 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Dec 26, 2025, 8:30 AM EST - 3 months ago

Adicet Bio Announces Reverse Stock Split

Nov 28, 2025, 2:23 PM EST - 4 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 5, 2025, 4:01 PM EST - 5 months ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 31, 2025, 4:59 PM EDT - 5 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2025, 7:00 AM EDT - 5 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

$Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)$

Oct 16, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 7, 2025, 12:35 PM EDT - 6 months ago

Adicet Bio, Inc. - Special Call

Oct 7, 2025, 11:05 AM EDT - 6 months ago

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Oct 7, 2025, 7:01 AM EDT - 6 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 6:45 AM EDT - 6 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:01 PM EDT - 8 months ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Jul 24, 2025, 7:00 AM EDT - 9 months ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

May 21, 2025, 4:00 PM EDT - 11 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 4:01 PM EDT - 11 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mar 31, 2025, 5:12 PM EDT - 1 year ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 6, 2025, 4:01 PM EST - 1 year ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 3, 2025, 7:00 AM EST - 1 year ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Feb 27, 2025, 7:00 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Feb 5, 2025, 7:10 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 29, 2025, 7:00 AM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 8, 2025, 4:10 PM EST - 1 year ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

May 29, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 14, 2024, 4:01 PM EDT - 2 years ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

SuperGreenToday Apr. 2 at 1:25 AM

0 · Reply

TheTurdFlusher Apr. 1 at 4:28 PM

$ACET man crazy this thing is still listed, the grift continues lol

0 · Reply

keepbuying Mar. 31 at 7:19 PM

$ACET would not be surprised to see an activist come at them given how below cash this is trading

0 · Reply

Nanu108 Mar. 31 at 3:11 AM

$ACET hot ACET today 10000 shares 52 low

0 · Reply

keepbuying Mar. 30 at 7:43 PM

2 · Reply

Ugbjjvgg Mar. 30 at 11:17 AM

$ACET I got into this stock by following the huge purchase by Orbimed, looking at their previous picks they have done seriously well. It's only matter of time this thing rockets.

0 · Reply

DCZ Mar. 27 at 4:56 PM

$ACET bought more this morning

1 · Reply

keepbuying Mar. 25 at 2:12 PM

0 · Reply

ChadWright85 Mar. 18 at 6:34 PM

$ACET Hard to see this turning around without a real catalyst.

1 · Reply

erevnon Mar. 13 at 2:56 PM

Guggenheim maintains Adicet Bio $ACET at Buy and lowers the price target from $128 to https://marketsblock.com/stock-upgrades-and-downgrades/

1 · Reply

DARKP00L Mar. 13 at 1:32 PM

$ACET 08:52 on Mar. 13 2026 Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $100 #tradeideas

0 · Reply

anachartanalyst Mar. 13 at 1:01 PM

$ACET https://anachart.com/wp-content/uploads/ana_temp/1773406881_soc-img.jpg

0 · Reply

StocktwitsEarnings Mar. 13 at 1:00 AM

$ACET Q4 '25 Earnings Results & Recap Adicet Bio Inc expects its $158.5 million in cash, cash equivalents, and short-term investments as of December 31, 2025, to fund operations for at least the next twelve months, with plans to meet with the FDA in Q2 2026 for prula-cel pivotal trial design.

0 · Reply

JJnewly18 Mar. 12 at 11:48 AM

$ACET should be a good day today

1 · Reply

MoneyAtlas Mar. 10 at 2:49 PM

$ACET someone knows that something is coming out

0 · Reply

aletz Mar. 6 at 9:15 AM

$ACET https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk122026/ Featured in the AI Catalyst Scanner for the second week of March. This scanner integrates advanced AI research with machine learning patterns, leveraging over a decade of data alongside catalyst-driven quality and technical indicators. Disclaimer: BSI score is a rating derived from combined AI and ML models and does not guarantee specific outcomes.

0 · Reply

OfficialStocktwitsUser Mar. 4 at 1:42 PM

$ACET RSI: 47.88, MACD: -0.1891 Vol: 0.29, MA20: 7.13, MA50: 7.76 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

520741888RC Mar. 4 at 1:34 PM

$ACET What time are earnings?

0 · Reply

King_of_Bio Mar. 2 at 11:17 PM

$ACET May rebound some but way too much risk short term...I'll keep an eye on this one.

0 · Reply

SuperGreenToday Mar. 2 at 3:03 PM

$ACET Share Price: $7.12 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.91 – $2.36 Target Zone: $3.61 – $4.41 Potential Upside: 78% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

vivalasvegasal Mar. 1 at 12:20 AM

$ACET well the market says different. Is someone short?

2 · Reply

vivalasvegasal Feb. 26 at 11:27 AM

$ACET look at all the institutions buys. Someone knows something

2 · Reply

Market Cap	67.08M
Revenue (ttm)	0.00
Net Income (ttm)	-116.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	64,000
Avg Vol	143,416
Day's Range	N/A - N/A
Shares Out	9.60M
Stochastic %K	94%
Beta	1.57
Analysts	Strong Sell
Price Target	$38.00